ARCHIVES

“Sloppy” Searle Studies Described By FDA At Kennedy Hearing; Rauscher “Outraged”

This article is from The Cancer Letter archive.

Vol. 02 No. 04 | January 23, 1976

Download PDF Visit The Full Archive

Related Articles

BSA Eliminates Second Review For P01 Grants; R01Payline To increase to 24th Percentile

November 23, 1997

Drug Discovery Group Announcement Issued

January 7, 1983

White House To Appoint Richard Klausner, Molecular Biologist, As NCI’s 11th Director

July 28, 1995

Drug Development: Herceptin Associated with 15 Deaths, Genentech Says

May 12, 2000

Attacks On Cancer, Program Peak Following Post Series; Defenders Cite Inaccuracies, Misconceptions

November 6, 1981

Letter: The Lesson From Dana-Farber

July 28, 1995